MediWound Ltd (NAS:MDWD)
$ 16.65 -0.26 (-1.54%) Market Cap: 179.59 Mil Enterprise Value: 160.58 Mil PE Ratio: 0 PB Ratio: 8.67 GF Score: 56/100

Q1 2022 Mediwound Ltd Earnings Call Transcript

May 17, 2022 / 12:30PM GMT
Release Date Price: $12.39 (-6.35%)
Operator

Good day, and welcome to the MediWound First Quarter 2022 Financial Results and Presentation of the EscharEx Phase II clinical trial results conference call. (Operator Instructions)

At this time, I would like to turn the conference over to Monique Kosse of LifeSci Advisors. Please go ahead.

Monique Kosse
LifeSci Advisors, LLC - MD

Thank you, operator, and welcome, everyone. Earlier today, MediWound issued a press release, announcing its first quarter 2022 financial results and provided a corporate update. We will be reviewing those results with the management team in addition to hearing from 2 KOLs on the results of the EscharEx U.S. Phase II trial, which were announced in a press release issued on May 12, 2022. You may access both releases on the company's website under the Investors tab.

With us today from management are Sharon Malka, Chief Executive Officer of MediWound; Ofer Gonen, Board member; and Boaz Gur-Lavie, Chief Financial Officer. Also joining us are Professor Lior Rosenberg, Chief Medical Officer; and Dr. Cyaandi Dove from

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot